Loading stock data…
NOVN.SW
CHF 113.70+0.34 (+0.30%)
Market ClosedLast close May 11
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novartis AG in the Healthcare sector is trading at $113.70. The stock is currently 13% below its 52-week high of $131.00, remaining 6.3% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why NOVN.SW maintains its current momentum and trend strength. The Whystock Score of 90/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current PriceCHF 113.70
Potential Upside
17.3%
Whystock Fair ValueCHF 133.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Hold
Mean targetCHF 120.70+6.2%
RangeCHF 94.09 – CHF 138.65
Fundamentals
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$220.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.60
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Strong income play. Yield provides a meaningful total return floor.
319.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
30.81%
Volume
Today's trading volume
2.22M
Recent News
Novartis AG (NVS) Expands U.S. Manufacturing Footprint with New Texas Site
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Novartis AG is also one of the best cancer stocks to buy for the long term. On May 7, NVS began construction on a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas. The project is part of the […]
Is It Too Late To Consider Novartis (SWX:NOVN) After Its Strong 1-Year Share Price Run?
Wondering if Novartis, at around its recent price of €113.36, still offers value, or if most of the easy gains are already behind it. The stock shows a mixed recent pattern, with a 2.2% decline over the last week and a 6.5% decline over the last month, while still sitting on a 4.5% gain year to date and a 28.5% return over the past year. These moves sit against a backdrop of ongoing attention on large pharmaceutical companies, including Novartis, as investors weigh long term pipelines,...
Construction begins on Novartis’ RLT centre in Texas, US
The site is expected to be operational in 2028, adding new roles in advanced manufacturing and bioengineering.
DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push
Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company continued investing heavily in its late-stage oncology pipeline.
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.